Synthetic Biologics Inc

ASE:SYN   3:41:13 PM EDT
0.33
-0.04 (-10.25%)
4:09:28 PM EDT: $0.33 0.00 (0.34%)
Products

Synthetic Biologics Says SYN-010 Is Unlikely To Meet Primary Objective By Time Enrollment Is Done

Published: 10/02/2020 11:29 GMT
Synthetic Biologics Inc (SYN) - Synthetic Biologics Provides Update on Investigator-sponsored Phase 2b Clinical Study of Syn-010 in Ibs-c Patients.
Synthetic Biologics - Concluded That Although Syn-010 Was Well-tolerated, It is Unlikely to Meet Its Primary Objective by Time Enrollment is Completed.
Synthetic Biologics Inc - Csmc Has Agreed to Discontinue Trial.